INTRODUCTION
Patients with neurologic conditions such as multiple sclerosis (MS) or spinal cord injury (SCI) often have neurogenic detrusor overactivity (NDO), which frequently results in urinary incontinence (UI) and high detrusor pressures [1, 2] . OnabotulinumtoxinA (BOTOX Ò , Allergan, Inc., Irvine, CA, USA) has been shown to be effective in the treatment of UI due to neurogenic detrusor overactivity in MS and SCI patients in phase 2 trials [3] [4] [5] and in two double-blind, placebo-controlled, phase 3 registration trials [6, 7] In this analysis, we further evaluated the efficacy and safety of onabotulinumtoxinA in the patients with the two neurologic etiologies (MS and SCI) separately. In addition, there were differences in regard to the use of anticholinergics. The study protocols required all patients to have been inadequately managed with at least one anticholinergic for their UI.
Some patients chose to continue using concomitant anticholinergics during the phase 3 studies, while others discontinued their anticholinergics prior to study start and remained off them throughout the study. The trial population thus consisted of two distinct subpopulations of patients: those taking onabotulinumtoxinA plus a concomitant anticholinergic medication, and those who received onabotulinumtoxinA alone.
Therefore, we also examined the impact of concomitant anticholinergic use/non-use on the efficacy and safety of onabotulinumtoxinA. Pooling the data from these trials provided a larger sample size to examine the effect of onabotulinumtoxinA 200U and 300U in these two specific subpopulations.
MATERIALS AND METHODS

Study Design
Details regarding study design and patient selection for these studies have been described previously [6, 7] . Briefly, the pivotal phase 
Efficacy and Safety Assessments
Change from baseline in weekly UI episodes, as well as the proportion of patients achieving C50% or 100% (complete dryness) reduction from baseline in UI episodes, was evaluated in all subgroups. Changes from baseline in maximum cystometric capacity (MCC), maximum detrusor pressure during first involuntary detrusor contraction (P detmaxIDC ), and percentage of patients with no involuntary detrusor contraction (IDC) were assessed.
Health-related QOL was evaluated using the change from baseline in the Incontinence Quality of Life (I-QOL) questionnaire total summary score [8] . Other assessments included the time to patient request for retreatment (measuring duration of effect) and a general satisfaction with treatment question (5-point rating scale from very satisfied to very dissatisfied). 
RESULTS
Efficacy and Safety by Etiology
The pooled ITT population from both studies combined (N = 691) included 381 patients with The change in the number of voluntary voids per week was examined in the noncatheterizing MS subpopulation. In contrast to SCI patients (13.5% voiding voluntarily at baseline), the majority of MS patients were not using CIC at baseline and were voiding spontaneously (69.6%). At week 6 following onabotulinumtoxinA treatment, the number of voluntary voids per week significantly decreased in MS patients who were not catheterizing at baseline compared with placebo (P B 0.05 for both doses; Fig. 2 ). The number of voluntary voids per week was not assessed in the SCI subpopulation because there were too few SCI patients who were not catheterizing at baseline to allow for a meaningful analysis.
Both MS and SCI patients treated with onabotulinumtoxinA showed significantly greater increases in MCC from baseline at (Table 2 ).
Both MS and SCI patients demonstrated significant improvements compared with placebo in I-QOL total summary score. The magnitude of change from baseline for both etiologies and both onabotulinumtoxinA doses was considerably greater than 11 points, which is the established minimally important difference (MID) [8] (Fig. 3 ).
In the MS population, the median time to patient request for retreatment was 295 and 307 days in the onabotulinumtoxinA 200U and 300U groups, respectively, whereas the SCI population requested retreatment earlier at 253 and 211 days in the onabotulinumtoxinA 200U and 300U groups, respectively. The median time to patient request for retreatment in the placebo group was 92 days for both etiologies, which is close to the minimum permissible time of 12 weeks after initial treatment (P\0.001 for both doses vs placebo). Adverse events across treatment cycle 1 for the MS and SCI populations are presented in Table 2 Urodynamic parameters by etiology and anticholinergic use (onabotulinumtoxinA 300U group) and in two SCI patients (both in the placebo group), and urosepsis was reported in two SCI patients (both in the placebo group).
The AE of urinary retention was further examined only in MS patients as most SCI patients were already performing CIC at study entry. Urinary retention appeared to show a dose-dependent increase in those MS patients who were not catheterizing at baseline. The rate The proportion of MS patients who initiated CIC for any reason in treatment cycle 1 was 17%, 40%, and 51% in the placebo, onabotulinumtoxinA 200U, and 300U groups, respectively. In these patients, the mean weekly frequency of CIC was not significantly different among groups; 13.4, 18.1, and 21.1 (P = 0.417) at week 6 after treatment and 9.4, 16.8, and 17.2 (P = 0.365) at week 12 in the placebo, onabotulinumtoxinA 200U, and 300U groups, respectively. The impact of initiation of CIC on patient satisfaction with treatment was assessed in MS patients (Fig. 5) . Satisfaction (defined as ''very satisfied'' or ''somewhat satisfied'') with onabotulinumtoxinA treatment remained high regardless of CIC initiation, with no statistically significant difference in satisfaction between the groups initiating CIC and those who did not for the 200U dose group (P = 0.167); however, a significant difference was observed for the 300U dose group (P = 0.048).
Efficacy and Safety by Baseline Anticholinergic Use
At the time of study entry, the majority of the patients had previously tried one (59.2%) or two (21.0%) different anticholinergics (Table 4) .
Most patients (76.1%) were inadequately managed with anticholinergics due to inadequate efficacy. In the pooled ITT population, 379/691 (55%) of patients were taking anticholinergics at baseline.
Significant reductions in weekly UI episodes
were observed with onabotulinumtoxinA 200U and 300U within the anticholinergic user and non-user subgroups (P B 0.05 vs placebo for both subgroups; Fig. 6a ). Comparison in UI at week 6 between the two subgroups did not yield statistically significant (P = 0.454) or clinically anticholinergic user and non-user subgroups achieved C50% or 100% reductions in weekly UI episodes at week 6 (Fig. 6b) . Dry rates for placebo, onabotulinumtoxinA 200U, and 300U were 7.9%, 36.7%, and 39.5% in the anticholinergic user and 10.9%, 37.4%, and 41.3% in the non-user subgroups, respectively (P\0.001 vs placebo each for users and nonusers).
Significant and similar increases in MCC in the onabotulinumtoxinA groups compared with placebo were seen in both anticholinergic users and non-users (Table 2 ). Decreases in P detmaxIDC and increases in I-QOL total summary scores were also similar regardless of anticholinergic use. Mean increases from baseline in I-QOL total summary scores at week 6 were 11.4, 28.7, and 31.9 for users (P = 0.001 vs placebo) and 10. showed that for the respective placebo, onabotulinumtoxinA 200U, and 300U groups, incidences of UTI were 43.1%, 58.7%, and 57.4% in users and 26.5%, 43.8%, and 54.5%
in non-users, and respective incidences of urinary retention were 2.9%, 14.9%, and 21.7% in users and 4.1%, 25.7%, and 24.8% in non-users. Table 3 continued AE, n 
DISCUSSION
These pooled data from two phase 3 trials include the largest cohorts of MS and SCI patients with UI due to NDO studied to date.
Treatment with onabotulinumtoxinA resulted in significant improvements in UI, urodynamic parameters, and QOL in these patients regardless of etiology. Consistent with previous analyses [6, 7] , there was no advantage in terms of efficacy for the 300U dose of onabotulinumtoxinA compared with the 200U dose in either the SCI or MS subpopulations. The only notable differences in efficacy between etiologies were that a larger placebo response was seen in change from baseline in UI episodes in the MS population, and a greater magnitude of reduction in P detmaxIDC was observed in the SCI population.
This larger placebo response in the MS population may reflect that the majority of MS patients were spontaneously voiding at baseline, and the observed placebo response is consistent with that of a non-neurogenic population [9] . In addition, just under 20% of the MS patients receiving placebo initiated CIC during the study. Many of these patients would likely have benefited from CIC prior to study entry, and the improved bladder emptying with CIC alone may have contributed to the improvements seen in MS patients receiving placebo. Nevertheless, the treatment effect Patients of both etiologies exhibited improvements in I-QOL total scores that were considerably greater than the established MID of 11 points [8] , with the magnitude of change being greatest in the MS population. This implies that these neurogenic populations have an improved health-related QOL when treated with onabotulinumtoxinA.
OnabotulinumtoxinA was well tolerated in both the MS and SCI populations, with the voiding pattern prior to treatment being the key difference between the two etiologies. The majority of MS patients were not using CIC prior to treatment, whereas the majority of SCI patients were. Therefore, the occurrence of urinary retention, initiation of CIC, and UTI rates were higher post treatment in the MS population. Nevertheless, in those MS patients not using CIC at baseline, the majority continued to avoid the need to use CIC for urinary retention post treatment (59/86
[68.6%]) or catheterized for urinary retention for a duration of B18 weeks (10/86 [11.6%] ). In those who initiated CIC, the mean frequency was about 2.5 times/day, indicating that many maintained some ability to spontaneously void.
MS patients' satisfaction with treatment appeared to be independent of initiation of CIC, in line with previous findings that patient QOL is not affected by initiation of CIC after treatment with onabotulinumtoxinA [10, 11] .
Furthermore, the higher incidence of UTI did not result in higher rates of complicated UTI.
In addition to examining the data by etiology, pooling the data provided a large sample size to examine onabotulinumtoxinA treatment with and without concomitant anticholinergic use. [12, 13] . This study found that improvements in UI, urodynamics, QOL, and duration of effect were independent of anticholinergic use. One possible explanation for the lack of an additional effect of anticholinergics in the presence of onabotulinumtoxinA may be that onabotulinumtoxinA, by directly blocking the release of acetylcholine into the neuromuscular junction [14] , may provide a more efficacious method for preventing muscarinic receptor activation than antimuscarinic drugs, which act by competitive blockade of the receptors [12] . A systematic review that examined studies in which patients were treated concomitantly with onabotulinumtoxinA and anticholinergics found that 28-58% of patients treated with onabotulinumtoxinA discontinued anticholinergics and most reduced their dose [15] . However, the pooled studies presented here were not designed to examine the effects of dose decreases or discontinuation of anticholinergics with onabotulinumtoxinA treatment. Rather, the protocols of these pivotal efficacy/safety trials required that anticholinergic doses remained constant during the study so as not to confound the results, and the trials in our analysis only included NDO patients who were inadequately managed by anticholinergics.
CONCLUSION
OnabotulinumtoxinA significantly improved UI episodes per week, urodynamic parameters, and QOL in both SCI and MS patients with UI due to NDO and regardless of concurrent anticholinergic use. OnabotulinumtoxinA was well tolerated in all subgroups.
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